Active Biotech AB (ACTI) — Cash Flow-to-Debt Ratio
Active Biotech AB (ACTI) has a Cash Flow-to-Debt Ratio of -0.58x as of September 2025, meaning its operating cash flow of Skr-7.20 Million could theoretically repay -1% of its total liabilities (Skr12.50 Million) in one year. See Active Biotech AB free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Active Biotech AB Cash Flow-to-Debt Ratio (2002–2024)
Historical debt coverage capacity for Active Biotech AB across 23 annual periods. Also explore ACTI year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Active Biotech AB (2002–2024)
Year-by-year debt coverage analysis for Active Biotech AB. For market capitalisation and broader financial context, see ACTI stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.63x | Skr-40.40 Million | Skr11.13 Million | ▼ -6.2% |
| 2023 | -3.42x | Skr-45.74 Million | Skr13.38 Million | ▼ -2.8% |
| 2022 | -3.33x | Skr-54.85 Million | Skr16.49 Million | ▲ +27.0% |
| 2021 | -4.56x | Skr-46.17 Million | Skr10.13 Million | ▼ -42.1% |
| 2020 | -3.21x | Skr-32.22 Million | Skr10.04 Million | ▼ -18.0% |
| 2019 | -2.72x | Skr-35.81 Million | Skr13.17 Million | ▼ -1335.0% |
| 2018 | -0.19x | Skr-40.65 Million | Skr214.52 Million | ▲ +7.7% |
| 2017 | -0.21x | Skr-46.45 Million | Skr226.14 Million | ▲ +35.3% |
| 2016 | -0.32x | Skr-73.16 Million | Skr230.32 Million | ▲ +60.8% |
| 2015 | -0.81x | Skr-217.89 Million | Skr268.84 Million | ▲ +3.7% |
| 2014 | -0.84x | Skr-267.09 Million | Skr317.21 Million | ▼ -198.4% |
| 2013 | -0.28x | Skr-102.25 Million | Skr362.40 Million | ▲ +58.1% |
| 2012 | -0.67x | Skr-240.40 Million | Skr356.82 Million | ▼ -411.4% |
| 2011 | -0.13x | Skr-46.97 Million | Skr356.53 Million | ▲ +78.4% |
| 2010 | -0.61x | Skr-196.32 Million | Skr321.34 Million | ▲ +15.8% |
| 2009 | -0.73x | Skr-224.77 Million | Skr309.86 Million | ▼ -40.7% |
| 2008 | -0.52x | Skr-159.46 Million | Skr309.34 Million | ▲ +17.2% |
| 2007 | -0.62x | Skr-186.70 Million | Skr299.97 Million | ▼ -149.9% |
| 2006 | -0.25x | Skr-100.13 Million | Skr402.04 Million | ▲ +49.4% |
| 2005 | -0.49x | Skr-192.51 Million | Skr391.05 Million | ▲ +50.5% |
| 2004 | -0.99x | Skr-149.65 Million | Skr150.59 Million | ▲ +80.8% |
| 2003 | -5.17x | Skr-288.83 Million | Skr55.82 Million | ▼ -54.7% |
| 2002 | -3.34x | Skr-291.71 Million | Skr87.24 Million | — |